Some breast cancer cells make a protein called Human Epidermal Growth factor receptor 2 (HER2). Patients with HER2 positive (HER2+) breast cancer receive medicine that attacks HER2, which helps these patients live longer. Some HER2 negative (HER2-) breast cancer patients also benefit from medicines that attack HER2, but we do not know why or which patients will benefit. This study uses a new imaging method, HER2-targeted PET/CT, to identify patients that may benefit from medicines that attack HER2. This is experimental.
Women age > 18 Biopsy proven HER2 negative primary breast cancer and biopsy proven metastatic disease. 5 or more foci of demonstrable metastases on recent imaging modalities (CT, MR, FDG PET/CT) ECOG performance score of 0-2
Exclusion Criteria:
Life expectancy < 3months Pregnancy or lactation Patients who cannot undergo PET/CT scanning because of weight limits CNS only disease on recent imaging
